January 18, 2011

Cambrex Zenara Manufacturing Facility Receives European GMP Approval

Contact Cambrex

Stephanie LaFiura, Investor Relations Associate
+1 201.804.3037

East Rutherford, NJ., and Hyderabad, India - Cambrex Corporation (NYSE: CBM, "Cambrex") announced today that the Danish Medicines Agency (DKMA) has issued a Certificate of Good Manufacturing Practice (GMP) compliance for its manufacturing site in Hyderabad, India, following an audit conducted in October 2010. The DKMA Certificate is accepted by all EU Health Authorities and by authorities of several other countries that recognize EU Certification.

Ashok Narasimhan, President of Cambrex Zenara, commented, "We are very pleased with the results of the DKMA inspection. This commercially important and significant milestone for Cambrex confirms our commitment to quality in every aspect of operations management and reflects our efforts to sustain and continuously improve quality platforms."

The DKMA certification allows Cambrex to expedite the European rollout of Nicotine Replacement Therapy (NRT) products (chewing gums, lozenges and mini-lozenges), in addition to offering finished dosage forms of other pharmaceutical products to our European customers through an integrated value chain.